No Data
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
KPC Pharmaceuticals,Inc.'s (SHSE:600422) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
KPC Pharmaceuticals' Unit Gets Nod to Add Indications for Colchicine Tablets
KPC Pharmaceuticals Gets China Clinical Trial Approval for Fatty Liver Drug
kpc pharmaceuticals, inc. (600422.SH): Received a notice of approval for drug clinical trials.
Gelonghui November 22nd | kpc pharmaceuticals, inc. (600422.SH) announced that the company recently received the KPC000154 tablet issued by the State Food and Drug Administration (Notice Number: 2024LP02631, 2024LP02632, hereinafter referred to as "the new drug") in accordance with the Category 1 New Drug Acceptance "Drug Clinical Trial Approval Notice", allowing the new drug to conduct related clinical trials. Research, KPC000154 tablets for the treatment of Nonalcoholic steatohepatitis (NASH).
KPC Pharmaceuticals,Inc (SHSE:600422) Not Lagging Market On Growth Or Pricing
